EcoDrugPlus

Protein Kinase D1

Ensembl ID : ENSNBRG00000022691
Gene Symbol: PRKD1
3 Cross references
204 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSNBRG00000008562
Gene Symbol: PRKD3
1 Cross references
201 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSNBRG00000009213
Gene Symbol: PRKD3
3 Cross references
209 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSNBRG00000012649
Gene Symbol: PRKDC
3 Cross references
184 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSNBRG00000007040
Gene Symbol: PPP3CA
4 Cross references
233 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSNBRG00000015120
Gene Symbol: PTPRB
3 Cross references
189 Possible Orthologues:

Protein-Cysteine N-Palmitoyltransferase Porcupine-Like

Ensembl ID : ENSNBRG00000009243
Gene Symbol: LOC102794997
3 Cross references
193 Possible Orthologues:

Protein-Tyrosine Kinase 2-Beta-Like

Ensembl ID : ENSNBRG00000019226
Gene Symbol: LOC102797664
3 Cross references
195 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSNBRG00000002708
Gene Symbol: LOC102798097
3 Cross references
216 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src-Like

Ensembl ID : ENSNBRG00000001659
Gene Symbol: LOC102780515
3 Cross references
197 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret-Like

Ensembl ID : ENSNBRG00000017065
Gene Symbol: LOC102797269
3 Cross references
204 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSNBRG00000002454
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).